Blood Cancer News and Research

RSS
Active ingredient in eye drops shows promise for treating aggressive blood cancer

Active ingredient in eye drops shows promise for treating aggressive blood cancer

Research advances offer hope for patient-tailored AML treatment

Research advances offer hope for patient-tailored AML treatment

New technology for profiling genetic makeup of myeloma tumor cells developed

New technology for profiling genetic makeup of myeloma tumor cells developed

Financial difficulties add to patients' cancer struggle

Financial difficulties add to patients' cancer struggle

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

Scientists use genetically engineered immune cells to fight Hodgkin and non-Hodgkin lymphoma cells

UK scientists find new way to identify patients with aggressive lymphoma

UK scientists find new way to identify patients with aggressive lymphoma

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

FDA approves new combination therapy for acute myeloid leukemia

FDA approves new combination therapy for acute myeloid leukemia

Researchers identify inconspicuous protein as key to aggressive blood cancer

Researchers identify inconspicuous protein as key to aggressive blood cancer

Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network

Abramson Cancer Center becomes the 28th member institution of National Comprehensive Cancer Network

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Researchers uncover link between RNA abnormalities and multiple myeloma progression

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

Study suggests new strategy to kill melanoma cells

Study suggests new strategy to kill melanoma cells

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Researchers develop promising targeted strategy to treat chemo-resistant blood cancer

Gene types that drive racial disparities in myeloma identified

Gene types that drive racial disparities in myeloma identified

'Supercharged' immune cells could help fight cancer

'Supercharged' immune cells could help fight cancer

Study sheds light on transport of enzyme involved in stem cell differentiation to DNA

Study sheds light on transport of enzyme involved in stem cell differentiation to DNA

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

New analysis confirms value of minimal residual disease as prognostic indicator in multiple myeloma

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients

FDA permits marketing of ClonoSEQ assay to detect minimal residual disease in blood cancer patients